Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03332940 · ClinicalTrials.gov registry record · Phase 1
Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH
A Phase 1 study, sponsored by Navidea Biopharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03332940 is a Phase 1 study that was terminated before completion, run by Navidea Biopharmaceuticals. The registered enrollment target is 6 participants.
The verdict
NCT03332940, a Phase 1 study, was terminated before completion, sponsored by Navidea Biopharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a prospective, open-label, multicenter, safety, comparative study of IV administered Tc99m-tilmanocept and unfiltered Tc99m sulfur colloid in the detection of and assessment of three dimensional tessellation localization to the liver in subjects with and without moderate to severe nonalcoholic steatohepatitis (NASH) by planar and SPECT/CT imaging. This study is designed to evaluate the safety and tolerability of Tc99m-tilmanocept in subjects with NASH.
Interventions
- DRUG Tc99m-tilmanocept
- DRUG Tc 99M Sulfur Colloid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-12-06 |
| Est. Completion | 2019-03-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03332940
The ClinicalTrials.gov registry entry for NCT03332940 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Navidea Biopharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tc99m-tilmanocept is the first listed.
NCT03332940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03332940 about?
NCT03332940 is a clinical study titled "Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH". This is a prospective, open-label, multicenter, safety, comparative study of IV administered Tc99m-tilmanocept and unfiltered Tc99m sulfur colloid in the detection of and assessment of three dimensional tessellation localization to the liver in subjects with and without moderate to severe nonalcohol...
What is the current status of trial NCT03332940?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2017-12-06. Estimated completion is 2019-03-10.
What interventions are being tested in trial NCT03332940?
The interventions under investigation include: Tc99m-tilmanocept (DRUG), Tc 99M Sulfur Colloid (DRUG).
Who is sponsoring clinical trial NCT03332940?
This trial is sponsored by Navidea Biopharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.